
On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.
Pfizer's sales jumped 10% year over year to $14.70 billion, above the consensus of $13.41 billion, reflecting an operational increase of 10%.